About elranatam ab bcmm
BCMA-directed bispecific antibody
Used for
- Treats adults with multiple myeloma that has returned or stopped responding after several prior treatments.
Usual adult dose
Given under the skin by a healthcare professional: 12 mg on day 1, 32 mg on day 4, then 76 mg weekly through week 24; afterward, every two weeks if responding.
Common side effects
- Cytokine release syndrome
- Infections
- Low blood-cell counts
- Nerve problems, including confusion or difficulty speaking
Important warnings
- Can cause life-threatening cytokine release syndrome and serious neurologic reactions; monitored dosing and premedication are required.
- Treatment should start in a hospital or appropriately equipped setting, with observation after early doses.
- May cause serious or fatal infections and low blood counts.
- Can harm an unborn baby; effective contraception is required during treatment and for four months afterward.
Pregnancy
May cause fetal harm. Pregnancy testing and effective contraception are recommended during treatment and for four months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for four months after the last dose.
Interactions
- No specific drug interactions are established; tell clinicians about all medicines and supplements.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.